Positron Emission Tomography Market Forecast 2025–2033
According to Renub Research Global Positron Emission Tomography (PET) Market is projected to increase from US$ 1.06 billion in 2024 to US$ 1.51 billion by 2033, expanding at a CAGR of 4.02% between 2025 and 2033. Rising demand for early-stage diagnostics, increasing incidence of chronic illnesses, advancements in imaging technologies, and rapid adoption of hybrid modalities like PET/CT and PET/MRI are major contributors to the market’s growth. The use of PET imaging is expanding across oncology, neurology, cardiology, and personalized medicine, solidifying its role as a vital diagnostic tool globally.
Positron Emission Tomography Market Outlook
Positron Emission Tomography (PET) is an advanced nuclear imaging technology that uses radioactive tracers to visualize metabolic activity within organs and tissues. It produces highly detailed 3D functional images that help clinicians detect abnormalities at a molecular level—often long before structural changes are visible through CT or MRI.
PET scans are frequently combined with other imaging modalities, such as CT for anatomical detail and MRI for soft-tissue contrast, resulting in integrated PET/CT or PET/MRI systems that deliver comprehensive diagnostic insights. These hybrid systems greatly enhance diagnostic accuracy, making PET indispensable in modern healthcare.
Globally, PET imaging is primarily used for:
- Oncology: Tumor detection, staging, metastasis monitoring, and therapy assessment
- Cardiology: Evaluation of myocardial perfusion, blood flow, and heart tissue viability
- Neurology: Diagnosis of Alzheimer’s disease, epilepsy, dementia, Parkinson’s disease, and brain tumors
The rising burden of chronic conditions, especially cancer and cardiovascular disease, has heightened clinical reliance on PET for early diagnosis and tailored treatment planning. Improvements in radiopharmaceutical development, expansion of nuclear medicine infrastructure, and supportive healthcare policies continue to fuel market growth worldwide.
Request a free sample copy of the report:https://www.renub.com/request-sample-page.php?gturl=positron-emission-tomography-market-p.php
Growth Drivers in the Positron Emission Tomography Market
Rising Incidence of Chronic Diseases
PET imaging demand is rising sharply due to increasing global prevalence of cancer, heart disease, neurological disorders, and chronic metabolic illnesses. Early detection is critical in managing these conditions, and PET scans provide unparalleled clarity by visualizing real-time metabolic activity.
In July 2024, data indicated that over 35.5 million adults in the U.S. are affected by chronic kidney disease (CKD), with diabetes and hypertension being leading causes. Alarmingly, 9 out of 10 CKD patients remain unaware of their diagnosis. Such statistics highlight the urgent need for advanced diagnostic tools like PET, which support early intervention and improved patient outcomes.
Advancements in Imaging Systems
Technological innovations have transformed PET imaging capabilities. Hybrid systems—such as PET/CT and PET/MRI—merge anatomical and functional insights, enabling exceptionally accurate diagnostics. Modern detectors provide faster image acquisition, higher sensitivity, and improved spatial resolution.
A key development occurred in September 2024, when GE HealthCare received FDA approval for Flyrcado™ (flurpiridaz F 18) injection, a next-generation PET myocardial perfusion imaging (MPI) agent. Designed for detecting coronary artery disease (CAD), the agent offers higher diagnostic accuracy than traditional SPECT systems. Moreover, Flyrcado can be manufactured offsite and delivered as a ready-to-use dose, increasing accessibility for healthcare centers.
Growing Applications in Personalized Medicine
Healthcare systems worldwide are shifting toward precision medicine—treatment tailored to individual patients based on biological markers. PET imaging plays a key role in monitoring therapeutic response, assessing molecular changes, and optimizing treatment strategies.
Investment in nuclear medicine and molecular imaging is rising accordingly. In May 2022, Mediso Ltd. expanded its market reach by acquiring UK-based Bartec Technologies Ltd, strengthening its capabilities in supplying PET imaging technologies. Personalized medicine approaches are expected to make PET even more indispensable in oncology, neurology, and cardiology.
Challenges in the Positron Emission Tomography Market
High Cost of PET Equipment and Procedures
PET scanners are expensive to purchase, install, and maintain. Radiopharmaceuticals also require costly production and specialized handling. These financial constraints limit PET adoption in low- and middle-income countries. Hospitals often struggle with the operational burdens associated with PET infrastructure, thereby reducing accessibility for patients.
Short Half-Life of Radioactive Tracers
Most PET tracers have extremely short half-lives, necessitating rapid production and delivery. This creates logistical challenges and requires proximity to cyclotrons or radiopharmacies. Remote regions and developing countries struggle with tracer availability, limiting widespread adoption of PET scanning. Developing longer-lasting tracers and improving transport logistics are key pathways to overcoming this barrier.
Full-Ring Positron Emission Tomography Scanners Market
Full-ring PET scanners dominate the market due to their superior sensitivity, higher accuracy, and full 360-degree data acquisition. They generate highly detailed 3D diagnostic images and offer faster scan times. These scanners are widely used in oncology, neurology, and cardiology.
Growing hospital infrastructure, investments in hybrid PET/CT and PET/MRI systems, and increasing clinical research in molecular imaging are expected to sustain demand for full-ring scanners globally.
Positron Emission Tomography Bismuth Germanium Oxide Market
Bismuth Germanium Oxide (BGO) detectors remain a reliable choice for PET systems due to their high density and strong gamma-ray detection efficiency. Although newer crystals like LYSO and LSO have gained popularity for higher light output, BGO is still used in cost-effective systems, especially in emerging markets. Its durability and affordability make it a preferred option for oncology and neurology centers in developing nations.
Cardiology Positron Emission Tomography Market
Cardiology is becoming a major growth area for PET imaging. PET can assess myocardial perfusion, evaluate coronary artery disease, and measure cardiac blood flow with unparalleled accuracy. Rising global prevalence of heart disease and the need for detailed diagnostic insights drive this segment.
Hybrid PET/CT scanners and new radiotracers support earlier detection and more precise treatment decisions. Adoption is especially increasing in specialized cardiac centers.
Oncology Positron Emission Tomography Market
Oncology represents the largest application segment for PET imaging. PET plays a central role in early detection, tumor staging, therapy monitoring, and recurrence evaluation. Greater cancer awareness, rising treatment volumes, and precision oncology programs support strong global demand.
Emerging radiopharmaceuticals and hybrid PET systems enhance accuracy and efficiency, reinforcing PET’s role in cancer management.
United States Positron Emission Tomography Market
The United States leads the global PET market due to its advanced healthcare infrastructure, high adoption of hybrid modalities, and significant cancer burden. Robust reimbursement systems, clinical research investment, and availability of radiopharmaceutical manufacturers support growth.
In July 2024, Positrigo gained FDA clearance for NeuroLF®, a portable brain PET system designed for diagnosing neurological diseases such as Alzheimer’s, Parkinson’s, and epilepsy. Such innovations further strengthen U.S. market leadership.
France Positron Emission Tomography Market
France benefits from strong government healthcare support, advanced imaging centers, and growing focus on neurological and cancer diagnostics. PET/CT systems are extensively used in major cities such as Paris and Lyon.
In April 2025, Telix Pharmaceuticals received marketing authorization for Illuccix®, a prostate cancer imaging agent that helps detect PSMA-positive lesions. This approval enhances accessibility and adoption of PET scans for precision oncology in France.
China Positron Emission Tomography Market
China’s PET market is expanding rapidly due to the rising incidence of cancer, expanding hospital infrastructure, and government-backed nuclear medicine centers. Growth is concentrated in urban regions, while increasing investment is supporting penetration into secondary cities.
In January 2022, Clario and XingImaging enhanced their partnership to conduct PET imaging clinical trials for new therapeutics, showcasing China’s increasing role in medical research and radiopharmaceutical development.
Brazil Positron Emission Tomography Market
Brazil’s PET market is fueled by growing awareness of early cancer detection and increased adoption of hybrid PET/CT solutions in urban areas. Government investment in healthcare modernization and private-sector partnerships with global imaging companies support growth. Challenges remain in rural access, but demand continues to rise in oncology and cardiology imaging.
Saudi Arabia Positron Emission Tomography Market
Saudi Arabia’s PET market is strengthening through Vision 2030 healthcare transformation efforts. Investments in nuclear medicine centers, specialty hospitals, and radiopharmaceutical production are improving accessibility.
In December 2024, King Abdulaziz University launched its first diagnostic PET/MRI service for Alzheimer’s disease, highlighting the country’s growing capabilities in molecular imaging.
Market Segmentation
Product Type
- Full-Ring PET Scanners
- Partial-Ring PET Scanners
Detector Type
- Bismuth Germanium Oxide
- Lutetium Oxyorthosilicate
- Lutetium Fine Silicate
- Lutetium Yttrium Orthosilicate
- Gadolinium Oxyorthosilicate
Application
- Cardiology
- Neurology
- Oncology
- Others
End-User
- Hospitals & Clinics
- Diagnostic Centers
- Others
Country Coverage
North America: United States, Canada
Europe: France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey
Asia Pacific: China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand
Latin America: Brazil, Mexico, Argentina
Middle East & Africa: Saudi Arabia, UAE, South Africa
Company Coverage – 5 Viewpoints
(Overview, Key Person, Recent Developments, SWOT Analysis, Revenue Analysis)
- Agfa Healthcare (Dedalus Group)
- GE Healthcare
- Koninklijke Philips NV
- Neusoft Medical Systems
- Positron Corporation
- Oncovision (Bruker)
- Mediso Medical Imaging Systems Ltd.
- Siemens Healthineers AG
- Segami Corporation
- Hitachi Ltd.